rheumatoid arthritis
Conditions
Interventions
Test group:Addition of tryptophan dietary supplement to csDMARDs (methotrexate + leflunomide/ hydroxychloroquine sulphate+L-Trp)
Control group:Use of csDMARDs (methotrexate + leflunomide/ hydroxychloroquine sulphate) therapeutic drugs
Sponsors
Dazhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) All met the 2010 American College of Rheumatology revised diagnostic criteria for RA; (2) RA patients aged =18 and =80 years with DAS28 =3.0; (3) Those who had received at least one csDMARDS (including methotrexate, hydroxychloroquine sulphate, leflunomide, and Iguratimod, etc.) with poor efficacy prior to enrolment; (4) Patients who were compliant, signed an informed consent form, and were able to complete the trial according to the protocol.
Exclusion criteria
Exclusion criteria: (1) Patients treated with biological agents; (2) Patients with malignant diseases such as peptic ulcer, haematological diseases, mental disorders and tumours; (3) Patients with previous or current medical history of inflammatory joint diseases other than rheumatoid arthritis, or patients with other systemic autoimmune diseases in combination; (4) Patients with a recent history of major surgery or trauma; (5) Presence of clinically significant serious poorly controlled concomitant disease as deemed by the investigator; (6) Patients who have poor compliance and are unable to co-operate in completing the trial; (7) Those with a history of depressive illness and taking related medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity score (DAS28);Erythrocyte sedimentation rate (ESR);C-reactive protein (CRP);Rheumatoid factor (RF);Swollen joint count (SJC28);Tender joint counts (TJC28);Assessment of joint functional activity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction; | — |
Countries
China
Contacts
Public ContactFanxin Zeng
Dazhou Central Hospital
Outcome results
None listed